S&P 500   2,746.90 (+3.29%)
DOW   23,386.11 (+3.23%)
QQQ   200.41 (+2.04%)
AAPL   265.69 (+2.41%)
FB   173.83 (+2.96%)
MSFT   165.38 (+1.16%)
GOOGL   1,209.87 (+2.31%)
AMZN   2,037.00 (+1.26%)
CGC   14.96 (+3.24%)
NVDA   266.75 (+2.98%)
BABA   195.10 (-1.46%)
MU   48.48 (+4.17%)
GE   7.30 (+3.84%)
TSLA   546.44 (+0.18%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.86 (+7.50%)
F   5.03 (+6.80%)
BAC   23.36 (+5.51%)
GILD   74.67 (+0.00%)
DIS   100.52 (-0.71%)
PRI   97.04 (+10.20%)
S&P 500   2,746.90 (+3.29%)
DOW   23,386.11 (+3.23%)
QQQ   200.41 (+2.04%)
AAPL   265.69 (+2.41%)
FB   173.83 (+2.96%)
MSFT   165.38 (+1.16%)
GOOGL   1,209.87 (+2.31%)
AMZN   2,037.00 (+1.26%)
CGC   14.96 (+3.24%)
NVDA   266.75 (+2.98%)
BABA   195.10 (-1.46%)
MU   48.48 (+4.17%)
GE   7.30 (+3.84%)
TSLA   546.44 (+0.18%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.86 (+7.50%)
F   5.03 (+6.80%)
BAC   23.36 (+5.51%)
GILD   74.67 (+0.00%)
DIS   100.52 (-0.71%)
PRI   97.04 (+10.20%)
S&P 500   2,746.90 (+3.29%)
DOW   23,386.11 (+3.23%)
QQQ   200.41 (+2.04%)
AAPL   265.69 (+2.41%)
FB   173.83 (+2.96%)
MSFT   165.38 (+1.16%)
GOOGL   1,209.87 (+2.31%)
AMZN   2,037.00 (+1.26%)
CGC   14.96 (+3.24%)
NVDA   266.75 (+2.98%)
BABA   195.10 (-1.46%)
MU   48.48 (+4.17%)
GE   7.30 (+3.84%)
TSLA   546.44 (+0.18%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.86 (+7.50%)
F   5.03 (+6.80%)
BAC   23.36 (+5.51%)
GILD   74.67 (+0.00%)
DIS   100.52 (-0.71%)
PRI   97.04 (+10.20%)
S&P 500   2,746.90 (+3.29%)
DOW   23,386.11 (+3.23%)
QQQ   200.41 (+2.04%)
AAPL   265.69 (+2.41%)
FB   173.83 (+2.96%)
MSFT   165.38 (+1.16%)
GOOGL   1,209.87 (+2.31%)
AMZN   2,037.00 (+1.26%)
CGC   14.96 (+3.24%)
NVDA   266.75 (+2.98%)
BABA   195.10 (-1.46%)
MU   48.48 (+4.17%)
GE   7.30 (+3.84%)
TSLA   546.44 (+0.18%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.86 (+7.50%)
F   5.03 (+6.80%)
BAC   23.36 (+5.51%)
GILD   74.67 (+0.00%)
DIS   100.52 (-0.71%)
PRI   97.04 (+10.20%)
Log in

NASDAQ:STIMNeuronetics Stock Price, Forecast & News

$1.75
+0.11 (+6.71 %)
(As of 04/8/2020 03:19 PM ET)
Add
Compare
Today's Range
$1.64
Now: $1.75
$1.76
50-Day Range
$1.28
MA: $2.23
$3.40
52-Week Range
$1.25
Now: $1.75
$17.76
Volume3,278 shs
Average Volume289,739 shs
Market Capitalization$32.67 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.
Read More
Neuronetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.15 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STIM
CUSIPN/A
CIKN/A
Phone610-640-4202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$62.66 million
Book Value$2.57 per share

Profitability

Net Income$-29,040,000.00

Miscellaneous

Employees191
Market Cap$32.67 million
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable

Receive STIM News and Ratings via Email

Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.


Neuronetics (NASDAQ:STIM) Frequently Asked Questions

How has Neuronetics' stock been impacted by COVID-19 (Coronavirus)?

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, STIM shares have decreased by 15.5% and is now trading at $1.75. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neuronetics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neuronetics.

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Neuronetics.

How were Neuronetics' earnings last quarter?

Neuronetics Inc (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, March, 3rd. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.44) by $0.03. The company had revenue of $17.36 million for the quarter, compared to analyst estimates of $17 million. Neuronetics had a negative return on equity of 51.08% and a negative net margin of 46.35%. View Neuronetics' earnings history.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics updated its FY 2020 Pre-Market earnings guidance on Tuesday, March, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $69-71 million, compared to the consensus revenue estimate of $70.56 million.

What price target have analysts set for STIM?

3 brokerages have issued twelve-month price targets for Neuronetics' stock. Their forecasts range from $6.00 to $11.00. On average, they expect Neuronetics' share price to reach $8.50 in the next year. This suggests a possible upside of 385.7% from the stock's current price. View analysts' price targets for Neuronetics.

Has Neuronetics been receiving favorable news coverage?

News stories about STIM stock have been trending very negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neuronetics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutNeuronetics.

Are investors shorting Neuronetics?

Neuronetics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 442,700 shares, an increase of 12.8% from the February 13th total of 392,500 shares. Based on an average daily volume of 211,500 shares, the short-interest ratio is currently 2.1 days. Currently, 5.6% of the shares of the stock are sold short. View Neuronetics' Current Options Chain.

Who are some of Neuronetics' key competitors?

What other stocks do shareholders of Neuronetics own?

Who are Neuronetics' key executives?

Neuronetics' management team includes the following people:
  • Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)
  • Mr. Peter L. Donato, CFO, VP & Corp. Sec. (Age 49)
  • Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)
  • Ms. Cassie Hallberg, VP of Marketing
  • Mr. Daniel Guthrie, Chief Commercial Officer & VP (Age 42)

When did Neuronetics IPO?

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $1.75.

How big of a company is Neuronetics?

Neuronetics has a market capitalization of $32.67 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe. View additional information about Neuronetics.

What is Neuronetics' official website?

The official website for Neuronetics is http://www.neurostar.com/.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel